Cargando…
Randomized Clinical Stroke Trials in 2007
This article reviews the randomized control trials (RCT’s) that were published in 2007 of emerging pharmacotherapies in patients with acute (≤ 2 weeks), sub-acute (2 to 12 weeks) and chronic (≥ 12 weeks) stroke. A Medline search generated 22 RCT’s in stroke in the year 2007 in the English language....
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627517/ https://www.ncbi.nlm.nih.gov/pubmed/19452012 http://dx.doi.org/10.2174/1874205X00802010055 |
_version_ | 1782163544510300160 |
---|---|
author | Rabadi, Meheroz H Blass, John P |
author_facet | Rabadi, Meheroz H Blass, John P |
author_sort | Rabadi, Meheroz H |
collection | PubMed |
description | This article reviews the randomized control trials (RCT’s) that were published in 2007 of emerging pharmacotherapies in patients with acute (≤ 2 weeks), sub-acute (2 to 12 weeks) and chronic (≥ 12 weeks) stroke. A Medline search generated 22 RCT’s in stroke in the year 2007 in the English language. These trials were primarily efficacy studies. These included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovascular disease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in Type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one FDA approved thrombolytic agent (r TPA); benefit of warfarin (an anticoagulant) in elderly patients with atrial fibrillation in the community; NXY (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a Calcium channel blocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage. Finally the role of non-pharmacotherapy like stents for patient’s with internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion and in vertebral artery stenosis. |
format | Text |
id | pubmed-2627517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-26275172009-05-18 Randomized Clinical Stroke Trials in 2007 Rabadi, Meheroz H Blass, John P Open Neurol J Article This article reviews the randomized control trials (RCT’s) that were published in 2007 of emerging pharmacotherapies in patients with acute (≤ 2 weeks), sub-acute (2 to 12 weeks) and chronic (≥ 12 weeks) stroke. A Medline search generated 22 RCT’s in stroke in the year 2007 in the English language. These trials were primarily efficacy studies. These included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovascular disease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in Type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one FDA approved thrombolytic agent (r TPA); benefit of warfarin (an anticoagulant) in elderly patients with atrial fibrillation in the community; NXY (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a Calcium channel blocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage. Finally the role of non-pharmacotherapy like stents for patient’s with internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion and in vertebral artery stenosis. Bentham Open 2008-10-31 /pmc/articles/PMC2627517/ /pubmed/19452012 http://dx.doi.org/10.2174/1874205X00802010055 Text en © Rabadi and Blass; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Rabadi, Meheroz H Blass, John P Randomized Clinical Stroke Trials in 2007 |
title | Randomized Clinical Stroke Trials in 2007 |
title_full | Randomized Clinical Stroke Trials in 2007 |
title_fullStr | Randomized Clinical Stroke Trials in 2007 |
title_full_unstemmed | Randomized Clinical Stroke Trials in 2007 |
title_short | Randomized Clinical Stroke Trials in 2007 |
title_sort | randomized clinical stroke trials in 2007 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627517/ https://www.ncbi.nlm.nih.gov/pubmed/19452012 http://dx.doi.org/10.2174/1874205X00802010055 |
work_keys_str_mv | AT rabadimeherozh randomizedclinicalstroketrialsin2007 AT blassjohnp randomizedclinicalstroketrialsin2007 |